507 related articles for article (PubMed ID: 32017293)
1. External Validation of a Venous Thromboembolic Risk Score for Cancer Outpatients with Solid Tumors: The COMPASS-CAT Venous Thromboembolism Risk Assessment Model.
Spyropoulos AC; Eldredge JB; Anand LN; Zhang M; Qiu M; Nourabadi S; Rosenberg DJ
Oncologist; 2020 Jul; 25(7):e1083-e1090. PubMed ID: 32017293
[TBL] [Abstract][Full Text] [Related]
2. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study.
Gerotziafas GT; Taher A; Abdel-Razeq H; AboElnazar E; Spyropoulos AC; El Shemmari S; Larsen AK; Elalamy I;
Oncologist; 2017 Oct; 22(10):1222-1231. PubMed ID: 28550032
[TBL] [Abstract][Full Text] [Related]
3. COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or immunotherapy, the CK-RAM study.
Abdel-Razeq H; Sharaf B; Al-Jaghbeer MJ; Abu-Fares H; Bater R; Shaer MA; Abu-Jaish H; Laban DA; Salamah O; Tamimi F; Ashouri K; Salameh T; Zughul R; Alhalaseh Y
J Thromb Thrombolysis; 2023 Oct; 56(3):447-453. PubMed ID: 37430158
[TBL] [Abstract][Full Text] [Related]
4. [Risk prediction of venous thromboembolism in non-small cell lung cancer patients based on COMPASS-CAT risk assessment model].
Wang YF; Ma F; Liu BL; Yang K; Li JL; Yu L
Zhonghua Zhong Liu Za Zhi; 2020 Apr; 42(4):340-345. PubMed ID: 32375452
[No Abstract] [Full Text] [Related]
5. Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients.
Rupa-Matysek J; Lembicz M; Rogowska EK; Gil L; Komarnicki M; Batura-Gabryel H
Med Oncol; 2018 Apr; 35(5):63. PubMed ID: 29616356
[TBL] [Abstract][Full Text] [Related]
6. Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer.
Cella CA; Knoedler M; Hall M; Arcopinto M; Bagnardi V; Gervaso L; Pellicori S; Spada F; Zampino MG; Ravenda PS; Frassoni S; Passaro A; Milano M; Laffi A; Fazio N; Lordick F
JAMA Netw Open; 2023 Feb; 6(2):e230010. PubMed ID: 36795409
[TBL] [Abstract][Full Text] [Related]
7. Comparison between the Khorana prediction score and Caprini risk assessment models for assessing the risk of venous thromboembolism in hospitalized patients with cancer: a retrospective case control study.
Hu Y; Li X; Zhou H; Lin P; Zhang J; Huang D; Qi M; Tang Y; Yi Q; Liang Z; Wang M
Interact Cardiovasc Thorac Surg; 2020 Oct; 31(4):454-460. PubMed ID: 32910201
[TBL] [Abstract][Full Text] [Related]
8. Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients.
Woller SC; Stevens SM; Jones JP; Lloyd JF; Evans RS; Aston VT; Elliott CG
Am J Med; 2011 Oct; 124(10):947-954.e2. PubMed ID: 21962315
[TBL] [Abstract][Full Text] [Related]
9. Investigation of two general venous thromboembolism risk-stratification models in predicting venous thromboembolic events in TB patients.
Sharif-Kashani B; Azimi M; Tabarsi P; Sadr M; Shirzadi S
Int J Mycobacteriol; 2022; 11(1):83-87. PubMed ID: 35295028
[TBL] [Abstract][Full Text] [Related]
10. Derivation, validation and assessment of a novel nomogram-based risk assessment model for venous thromboembolism in hospitalized patients with lung cancer: A retrospective case control study.
Li H; Tian Y; Niu H; He L; Cao G; Zhang C; Kaiweisierkezi K; Luo Q
Front Oncol; 2022; 12():988287. PubMed ID: 36300098
[TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolism (VTE) risk stratification in general medical patients at an academic medical center.
Fritz MK; Kincaid SE; Sargent CG; Green AH; Davis GA
J Thromb Thrombolysis; 2021 Jan; 51(1):67-73. PubMed ID: 32447745
[TBL] [Abstract][Full Text] [Related]
12. External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-19.
Goldin M; Lin SK; Kohn N; Qiu M; Cohen SL; Barish MA; Gianos E; Diaz A; Richardson S; Giannis D; Chatterjee S; Coppa K; Hirsch JS; Ngu S; Firoozan S; McGinn T; Spyropoulos AC
J Thromb Thrombolysis; 2021 Nov; 52(4):1032-1035. PubMed ID: 34146235
[TBL] [Abstract][Full Text] [Related]
13. Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study.
Cella CA; Di Minno G; Carlomagno C; Arcopinto M; Cerbone AM; Matano E; Tufano A; Lordick F; De Simone B; Muehlberg KS; Bruzzese D; Attademo L; Arturo C; Sodano M; Moretto R; La Fata E; De Placido S
Oncologist; 2017 May; 22(5):601-608. PubMed ID: 28424324
[TBL] [Abstract][Full Text] [Related]
14. Risk Assessment Models for Venous Thromboembolism in Medical Inpatients.
Häfliger E; Kopp B; Darbellay Farhoumand P; Choffat D; Rossel JB; Reny JL; Aujesky D; Méan M; Baumgartner C
JAMA Netw Open; 2024 May; 7(5):e249980. PubMed ID: 38728035
[TBL] [Abstract][Full Text] [Related]
15. A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts.
Muñoz A; Ay C; Grilz E; López S; Font C; Pachón V; Castellón V; Martínez-Marín V; Salgado M; Martínez E; Calzas J; Ortega L; Rupérez A; Salas E; Pabinger I; Soria JM
J Clin Oncol; 2023 Jun; 41(16):2911-2925. PubMed ID: 36730884
[TBL] [Abstract][Full Text] [Related]
16. Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.
Syrigos K; Grapsa D; Sangare R; Evmorfiadis I; Larsen AK; Van Dreden P; Boura P; Charpidou A; Kotteas E; Sergentanis TN; Elalamy I; Falanga A; Gerotziafas GT
Oncologist; 2018 Nov; 23(11):1372-1381. PubMed ID: 30104289
[TBL] [Abstract][Full Text] [Related]
17. External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR).
Mahan CE; Liu Y; Turpie AG; Vu JT; Heddle N; Cook RJ; Dairkee U; Spyropoulos AC
Thromb Haemost; 2014 Oct; 112(4):692-9. PubMed ID: 24990708
[TBL] [Abstract][Full Text] [Related]
18. Overview of risk assessment models for venous thromboembolism in ambulatory patients with cancer.
Gerotziafas GT; Mahé I; Lefkou E; AboElnazar E; Abdel-Razeq H; Taher A; Antic D; Elalamy I; Syrigos K; Van Dreden P
Thromb Res; 2020 Jul; 191 Suppl 1():S50-S57. PubMed ID: 32736779
[TBL] [Abstract][Full Text] [Related]
19. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States.
Khorana AA; Dalal M; Lin J; Connolly GC
Cancer; 2013 Feb; 119(3):648-55. PubMed ID: 22893596
[TBL] [Abstract][Full Text] [Related]
20. The use of weighted and scored risk assessment models for venous thromboembolism.
Spyropoulos AC; McGinn T; Khorana AA
Thromb Haemost; 2012 Dec; 108(6):1072-6. PubMed ID: 23138506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
